Hexocyclium
Tral (hexocyclium) is a small molecule pharmaceutical. Hexocyclium was first approved as Tral on 1982-01-01. It is known to target muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M1.
| Trade Name | Tral |
|---|---|
| Common Name | Hexocyclium |
| Indication | |
| Drug Class | Quaternary ammonium derivatives |
